Formulary Watch reports that the FDA has expanded the indication for the Pfizer drug palbociclib to treat breast cancer in male patients. Janet Serluco, VP, Access Experience Team, Oncology Lead at Precision Medicine Group, comments on the implications for patients and for Pfizer.
